Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 18, 2007
Amneal Completes Acquisition of Liquid Form Generic Pharmaceuticals Manufacturing Plant
PDF format download (opens in new window)
Dec 17, 2007
IMPAX Announces FDA Acceptance of ANDA for Generic Version of Opana(R) ER
Dec 06, 2007
IMPAX Submits Additional Information to FDA Related to ANDA For Generic Version of Opana(R) ER
Nov 27, 2007
Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
PDF format download (opens in new window)
Nov 27, 2007
IMPAX to Reinitiate Sales of Limited Quantity of Generic OxyContin(R)
Nov 19, 2007
IMPAX Comments on Lawsuit Related to Generic Version of Opana(R) ER
Oct 18, 2007
Amneal & Indoco Remedies Finalize Long Term Joint Venture to Develop and Market Generic Ophthalmic Pharmaceuticals
PDF format download (opens in new window)
Oct 18, 2007
IMPAX Announces Tentative Approval of Generic Effexor XR(R)
Oct 04, 2007
IMPAX Comments on Status of ANDA for Generic Opana(R) ER
Sep 27, 2007
FTC Challenges Mylan’s Proposed Acquisition of Merck’s Generic Subsidiary
PDF format download (opens in new window)
Sep 17, 2007
Amneal Pharmaceuticals Profile in Chain Drug Review
PDF format download (opens in new window)
Aug 15, 2007
IMPAX Names Larry Hsu as CEO Effective October 1, 2006
Jul 27, 2007
IMPAX Announces Ruling Related to Generic Rilutek(R)
Jul 25, 2007
IMPAX Achieves Milestone in Efforts to File Delinquent Periodic Reports
Jun 19, 2007
IMPAX Announces Lawsuit Related to Generic Version of Depakote ER
Jun 08, 2007
IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders
Jun 01, 2007
IMPAX Announces Decision on Generic Prilosec(R) Litigation
May 31, 2007
Amneal Announces Acquisition of Akyma Pharmaceuticals
PDF format download (opens in new window)
May 29, 2007
IMPAX Receives Final FDA Approval for Generic Xanax(R) XR Extended Release Tablets
May 25, 2007
IMPAX Announces Dismissal of Generic OxyContin Litigation
May 22, 2007
IMPAX Seeks SEC Review of Initial Decision
May 16, 2007
IMPAX to Present at the Citigroup 2007 Healthcare Conference
May 09, 2007
IMPAX Receives Final FDA Approval for Generic Ditropan(R) XL 5 mg and 10 mg
May 01, 2007
IMPAX Reports SEC Actions
Apr 03, 2007
IMPAX Announces FDA Approval of Generic Corzide
Apr 02, 2007
IMPAX Settles Oxycontin(R) Litigation; Amends Marketing Agreement with DAVA Pharmaceuticals
Mar 14, 2007
IMPAX to Present at the Lehman Brothers 10th Annual Global Healthcare Conference
Mar 05, 2007
IMPAX Settles Patent Litigation Related to Generic Wellbutrin(R) XL
Feb 02, 2007
IMPAX Files Revised Submission with Office of the Chief Accountant of the SEC
Jan 31, 2007
IMPAX to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 18, 2007
IMPAX Files Amendment to Vadova(TM) NDA
Jan 02, 2007
IMPAX Reports SEC Actions

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top